Cancer Genetics, Inc., a leader in drug discovery and preclinical oncology and immuno-oncology services, announced that it has entered into securities purchase agreements with certain healthcare-focused institutional investors to raise approximately $17.5 million through the issuance of 2,777,778 shares of its common stock at a purchase price of $6.30 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
February 10, 2021
· 4 min read